Kestra Medical Technologies, Ltd. (KMTS) Income Statement
KMTS FY2026 at a glance
Fiscal year ended April 30, 2026 · U.S. dollarsKMTS revenue and net income
Where KMTS's revenue goes
FY2026Each bar shows an amount and its share of revenue. KMTS kept −138.4% of revenue as net income.
KMTS profit margins
KMTS growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +59.0% | +131.9% | — | — |
| Gross profit | +101.8% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KMTS quarterly EPS vs estimates
Kestra Medical Technologies beat the analyst EPS estimate in 3 of the last 7 quarters. Next report: December 10, 2026 (estimate $-0.61).
KMTS income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Revenue | $95.1M | $59.8M | $27.8M | $7.6M | $0 | $0 |
| Cost of revenue | $46.3M | $35.6M | $27.5M | $18.3M | — | — |
| Gross profit | $48.9M | $24.2M | $362,000 | −$10.7M | — | — |
| Research & development | $19.5M | $15.7M | $15.5M | $15.8M | $18.8M | $22.8M |
| Sales, general & admin | $164.1M | $114.9M | $69.9M | $54.0M | $13.9M | $6.5M |
| Total operating expenses | $183.6M | $130.6M | $85.4M | $69.8M | $32.7M | $29.3M |
| Operating income | −$134.7M | −$106.4M | −$85.1M | −$80.4M | −$32.7M | −$29.3M |
| Interest income | $8.4M | $3.2M | $0 | — | — | — |
| Interest expense | $7.5M | $7.7M | $6.2M | $5.6M | $1.2M | $0 |
| Income before taxes | −$131.3M | −$113.7M | −$94.1M | −$84.2M | −$33.9M | −$29.3M |
| Income taxes | $294,000 | $135,000 | $24,000 | $15,000 | $187,000 | $148,000 |
| Net income | −$131.6M | −$113.8M | −$94.1M | −$84.2M | −$34.1M | −$29.5M |
| EBITDA | −$136.9M | −$98.0M | −$76.3M | −$73.7M | −$32.3M | −$28.8M |
| EPS (diluted) | −$1.88 | −$2.24 | −$1.90 | — | −$0.69 | −$0.59 |
| Gross margin | 51.4% | 40.5% | 1.3% | −139.6% | — | — |
| Operating margin | −141.6% | −177.8% | −305.8% | −1,054.0% | — | — |
| Net margin | −138.4% | −190.3% | −338.4% | −1,104.0% | — | — |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Jul '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.0M | $28.6M | $24.6M | $22.6M | $19.4M | $17.2M | $15.1M | $14.7M | $12.8M | $10.1M | $8.3M | $0 |
| Cost of revenue | $13.5M | $13.0M | $11.6M | $11.1M | $10.5M | $9.6M | $8.5M | $8.9M | $8.6M | $8.7M | $7.4M | — |
| Gross profit | $17.5M | $15.7M | $12.9M | $11.4M | $8.9M | $7.6M | $6.5M | $5.8M | $4.2M | $1.4M | $880,000 | — |
| Research & development | $6.8M | $5.6M | $5.0M | $4.9M | $4.0M | $5.4M | $3.4M | $3.5M | $3.4M | $3.8M | $3.7M | $4.9M |
| Sales, general & admin | $48.4M | $49.4M | $42.7M | $38.3M | $33.7M | $50.5M | $23.8M | $21.5M | $19.2M | $17.9M | $17.1M | $7.4M |
| Total operating expenses | $55.2M | $55.0M | $47.7M | $43.2M | $37.7M | $55.8M | $27.1M | $25.0M | $22.6M | $21.7M | $20.8M | $12.3M |
| Operating income | −$37.7M | −$39.3M | −$34.8M | −$31.8M | −$28.9M | −$48.2M | −$20.6M | −$19.1M | −$18.4M | −$20.3M | −$19.9M | −$12.3M |
| Interest income | $2.1M | $2.2M | $2.2M | $1.8M | $2.2M | $1.7M | $628,000 | $878,000 | $37,000 | — | $0 | — |
| Interest expense | $1.9M | $1.8M | $1.9M | $1.9M | $1.9M | $1.8M | $1.8M | $1.4M | $1.9M | $1.9M | $1.7M | $847,000 |
| Income before taxes | −$44.0M | −$38.6M | −$34.1M | −$32.8M | −$25.8M | −$51.0M | −$21.7M | −$20.6M | −$20.3M | −$22.3M | −$21.6M | −$13.1M |
| Income taxes | $50,000 | $192,000 | $35,000 | $34,000 | $33,000 | $102,000 | $18,000 | $8,000 | $7,000 | −$27,000 | $14,000 | $57,000 |
| Net income | −$44.1M | −$38.8M | −$34.2M | −$32.8M | −$25.8M | −$52.1M | −$21.5M | −$20.4M | −$19.9M | −$22.3M | −$21.6M | −$13.1M |
| EBITDA | −$35.0M | −$37.0M | −$30.3M | −$28.5M | −$21.9M | −$47.4M | −$18.1M | −$17.3M | −$16.1M | −$16.9M | −$16.6M | −$12.2M |
| EPS (diluted) | −$0.75 | −$0.67 | −$0.40 | −$0.45 | −$0.36 | −$1.06 | −$1.18 | — | — | — | — | — |
| Gross margin | 56.5% | 54.8% | 52.6% | 50.6% | 45.7% | 44.3% | 43.4% | 39.6% | 32.9% | 13.9% | 10.6% | — |
| Operating margin | −121.6% | −137.4% | −141.6% | −140.7% | −149.1% | −279.8% | −136.5% | −130.1% | −144.2% | −202.4% | −241.0% | — |
| Net margin | −142.3% | −135.6% | −139.2% | −145.3% | −133.3% | −302.1% | −142.5% | −138.5% | −155.6% | −221.6% | −261.2% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KMTS's financial statements (latest annual report filed July 14, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KMTS financial results
In fiscal year 2026 (ended April 30, 2026), Kestra Medical Technologies reported revenue of $95.1 million, up 59.0% from the year before. It had a net loss of $131.6 million, a net profit margin of −138.4%. Diluted earnings per share came to −$1.88.
See the KMTS stock overview for the latest quote and news, or the KMTS chart for price history and technical indicators.
KMTS income statement FAQ
What is Kestra Medical Technologies's annual revenue?
Kestra Medical Technologies reported total revenue of $95.1 million for fiscal year 2026, which ended on April 30, 2026. That was up 59.0% from $59.8 million the previous year.
Is Kestra Medical Technologies profitable?
No. Kestra Medical Technologies reported a net loss of $131.6 million in fiscal 2026, a net profit margin of −138.4%; its operating margin was −141.6%.
What is Kestra Medical Technologies's gross margin?
Kestra Medical Technologies's gross margin was 51.4% in fiscal 2026: for every $100 of revenue, Kestra Medical Technologies kept $51 after the direct cost of its products and services.
How much does Kestra Medical Technologies spend on research and development?
Kestra Medical Technologies spent $19.5 million on research and development in fiscal 2026, 20.5% of revenue.
What are Kestra Medical Technologies's earnings per share?
Kestra Medical Technologies earned $-1.88 per diluted share in fiscal 2026, compared with $-2.24 a year earlier.
When will Kestra Medical Technologies report its next earnings?
Kestra Medical Technologies is expected to report results for the quarter ending October 31, 2026 on December 10, 2026.
When does Kestra Medical Technologies's fiscal year end?
Kestra Medical Technologies's fiscal year ends in April. The latest annual report covers the year ended April 30, 2026 and was filed on July 14, 2026.